CTMX
CytomX Therapeutics, Inc.
Biotechnology
Market Cap$681M
5Y Perf.-54.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CTMX vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+6.1%
CTMX vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CTMX | IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $681M | $5.53B |
| Revenue (TTM) | $36M | $0.00 |
| Net Income (TTM) | $-59M | $-464M |
| Gross Margin | 69.7% | — |
| Operating Margin | -181.9% | — |
| Total Debt | $4M | $98K |
| Cash & Equiv. | $13M | $714M |
CTMX vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CTMX
IMVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| CytomX Therapeutics… (CTMX) | 100 | 45.1 | -54.9% |
| Immunovant, Inc. (IMVT) | 100 | 106.1 | +6.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CTMX vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CTMX and IMVT are tied at the top with 3 categories each — the right choice depends on your priorities. Immunovant, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
CTMX
CytomX Therapeutics, Inc.
The Income Pick
CTMX carries the broadest edge in this set and is the clearest fit for dividends and momentum.
- 0.5% yield; the other pay no meaningful dividend
- +316.4% vs IMVT's +96.1%
- -28.0% ROA vs IMVT's -44.1%
Best for: dividends and momentum
IMVT
Immunovant, Inc.
The Income Pick
IMVT is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.37
- EPS growth -45.2%
- 173.6% 10Y total return vs CTMX's -66.9%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IMVT | -21.3% revenue growth vs CTMX's -44.8% |
| Quality / Margins | IMVT | 3.2% margin vs CTMX's -166.4% |
| Stability / Safety | IMVT | Beta 1.37 vs CTMX's 1.48, lower leverage |
| Dividends | CTMX | 0.5% yield; the other pay no meaningful dividend |
| Momentum (1Y) | CTMX | +316.4% vs IMVT's +96.1% |
| Efficiency (ROA) | CTMX | -28.0% ROA vs IMVT's -44.1% |
CTMX vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIMVTLAGGINGCTMX
CTMXCytomX Therapeutics, …
1leads
IMVTImmunovant, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs CTMXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IMVT1/1
Valuation MetricsMultiples, price ratios, and targets
CTMX2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
IMVT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IMVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CTMX and IMVT operate at a comparable scale, with $36M and $0 in trailing revenue.
| Metric | CTMXCytomX Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $36M | $0 |
| EBITDAEarnings before interest/tax | -$64M | -$487M |
| Net IncomeAfter-tax profit | -$59M | -$464M |
| Free Cash FlowCash after capex | -$80M | -$423M |
| Gross MarginGross profit ÷ Revenue | +69.7% | — |
| Operating MarginEBIT ÷ Revenue | -181.9% | — |
| Net MarginNet income ÷ Revenue | -166.4% | — |
| FCF MarginFCF ÷ Revenue | -2.3% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -79.9% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -137.0% | +19.7% |
IMVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
CTMX leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | CTMXCytomX Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $681M | $5.5B |
| Enterprise ValueMkt cap + debt − cash | $673M | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -26.67x | -9.97x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 8.94x | — |
| Price / BookPrice ÷ Book value/share | 5.57x | 5.83x |
| Price / FCFMarket cap ÷ FCF | — | — |
CTMX leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — CTMX and IMVT each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
CTMX delivers a -36.6% return on equity — every $100 of shareholder capital generates $-37 in annual profit, vs $-47 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CTMX's 0.04x.
| Metric | CTMXCytomX Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -36.6% | -47.1% |
| ROA (TTM)Return on assets | -28.0% | -44.1% |
| ROICReturn on invested capital | -47.7% | — |
| ROCEReturn on capital employed | -28.0% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.04x | 0.00x |
| Net DebtTotal debt minus cash | -$8M | -$714M |
| Cash & Equiv.Liquid assets | $13M | $714M |
| Total DebtShort + long-term debt | $4M | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Evenly matched — CTMX and IMVT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — CTMX and IMVT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,241 today (with dividends reinvested), compared to $4,678 for CTMX. Over the past 12 months, CTMX leads with a +316.4% total return vs IMVT's +96.1%. The 3-year compound annual growth rate (CAGR) favors CTMX at 33.5% vs IMVT's 12.1% — a key indicator of consistent wealth creation.
| Metric | CTMXCytomX Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -5.9% | +5.1% |
| 1-Year ReturnPast 12 months | +316.4% | +96.1% |
| 3-Year ReturnCumulative with dividends | +138.1% | +40.9% |
| 5-Year ReturnCumulative with dividends | -53.2% | +62.4% |
| 10-Year ReturnCumulative with dividends | -66.9% | +173.6% |
| CAGR (3Y)Annualised 3-year return | +33.5% | +12.1% |
Evenly matched — CTMX and IMVT each lead in 3 of 6 comparable metrics.
Risk & Volatility
IMVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
IMVT is the less volatile stock with a 1.37 beta — it tends to amplify market swings less than CTMX's 1.48 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs CTMX's 48.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CTMXCytomX Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.48x | 1.37x |
| 52-Week HighHighest price in past year | $8.20 | $30.09 |
| 52-Week LowLowest price in past year | $0.91 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +48.8% | +90.5% |
| RSI (14)Momentum oscillator 0–100 | 41.3 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 7.2M | 1.4M |
IMVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CTMX as "Buy" and IMVT as "Buy". Consensus price targets imply 190.0% upside for CTMX (target: $12) vs 67.2% for IMVT (target: $46). CTMX is the only dividend payer here at 0.54% yield — a key consideration for income-focused portfolios.
| Metric | CTMXCytomX Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $11.60 | $45.50 |
| # AnalystsCovering analysts | 21 | 23 |
| Dividend YieldAnnual dividend ÷ price | +0.5% | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | $0.02 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IMVT leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). CTMX leads in 1 (Valuation Metrics). 2 tied.
Best OverallImmunovant, Inc. (IMVT)Leads 2 of 6 categories
Loading custom metrics...
CTMX vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CTMX or IMVT a better buy right now?
Analysts rate CytomX Therapeutics, Inc.
(CTMX) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CTMX or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +62. 4%, compared to -53. 2% for CytomX Therapeutics, Inc. (CTMX). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus CTMX's -66. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CTMX or IMVT?
By beta (market sensitivity over 5 years), Immunovant, Inc.
(IMVT) is the lower-risk stock at 1. 37β versus CytomX Therapeutics, Inc. 's 1. 48β — meaning CTMX is approximately 8% more volatile than IMVT relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 4% for CytomX Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CTMX or IMVT?
On earnings-per-share growth, the picture is similar: Immunovant, Inc.
grew EPS -45. 2% year-over-year, compared to -139. 5% for CytomX Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CTMX or IMVT?
Immunovant, Inc.
(IMVT) is the more profitable company, earning 0. 0% net margin versus -22. 8% for CytomX Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0. 0% versus -25. 7% for CTMX. At the gross margin level — before operating expenses — CTMX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CTMX or IMVT?
In this comparison, CTMX (0.
5% yield) pays a dividend. IMVT does not pay a meaningful dividend and should not be held primarily for income.
07Is CTMX or IMVT better for a retirement portfolio?
For long-horizon retirement investors, CytomX Therapeutics, Inc.
(CTMX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 5% yield). Both have compounded well over 10 years (CTMX: -66. 9%, IMVT: +173. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CTMX and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
CTMX pays a dividend while IMVT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.